A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment

被引：0
作者：
Takashi Yoshida
Toshiaki Tanaka
Tetsuya Shindo
Yuki Kyoda
Kohei Hashimoto
Ko Kobayashi
Tadashi Hasegawa
Naoya Masumori
机构：
[1] Sapporo Medical University,Department of Urology
[2] Sapporo Medical University,Department of Surgical Pathology
来源：
International Cancer Conference Journal | 2022年 / 11卷
关键词：
Immune checkpoint inhibitor; Nivolumab; Renal cell carcinoma; Xp11.2 translocation renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A female patient with Xp11.2 translocation renal cell carcinoma developed lung metastasis 24 months after partial nephrectomy that was performed at the age of 32. Sunitinib, everolimus, axitinib, temsirolimus and pazopanib were sequentially administered for 55 months and disease progression was observed. Then nivolumab was started as 6th-line treatment. After a transient increase in tumor size, metastatic tumors started to shrink. Eventually, nivolumab provided a partial response with a 35% reduction of tumor size at 50 months and freedom from progression for 60 months. The present case suggests that immune checkpoint inhibitors are effective in selected cases with Xp11.2 translocation renal cell carcinoma.
引用
收藏
页码：134 / 137
页数：3
相关论文
共 50 条
[31]   PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness [J].
Chang, Kun ;
Qu, Yuanyuan ;
Dai, Bo ;
Zhao, Jian-Yuan ;
Gan, Hualei ;
Shi, Guohai ;
Zhu, Yiping ;
Shen, Yijun ;
Zhu, Yao ;
Zhang, Hailiang ;
Ye, Dingwei .
SCIENTIFIC REPORTS, 2017, 7
[32]   Pregnant patient with Xp11.2/transcription factor E3 translocation renal cell carcinoma: a case report and literature review [J].
Wang, Yanchen ;
Guo, Xiaoyan ;
Meng, Zhe ;
Cui, Yong ;
Sun, Yaofei .
FRONTIERS IN ONCOLOGY, 2024, 14
[33]   Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report [J].
Ikarashi, Daiki ;
Nakamura, Yasuyuki ;
Shimodate, Hitoshi ;
Usui, Yoshitaka ;
Ujiie, Takashi ;
Ohara, Wataru .
UROLOGY CASE REPORTS, 2019, 24
[34]   Contrast-Enhanced Ultrasound Features of Adult Xp11.2 Translocation Renal Cell Carcinoma Differential Diagnosis With Three Main Renal Cell Carcinoma Subtypes [J].
Ma, Wenliang ;
Zhang, Fan ;
Huang, Haifeng ;
Wang, Wei ;
Zhu, Yiqi ;
Lu, Yanwen ;
Guo, Hongqian ;
Gan, Weidong .
JOURNAL OF ULTRASOUND IN MEDICINE, 2022, 41 (11) :2673-2685
[35]   ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma [J].
Zhu, Yiqi ;
Liu, Ning ;
Guo, Wei ;
Pu, Xiaohong ;
Guo, Hongqian ;
Gan, Weidong ;
Li, Dongmei .
PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (12)
[36]   Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: A case report and literature review [J].
Yang, Denghao ;
Tang, Wen ;
Liu, Mingwen ;
Xie, Zhifei ;
Shi, Fei ;
Zhao, Zeju ;
Yang, Xiaorong ;
Wu, Tao .
ONCOLOGY LETTERS, 2024, 27 (01)
[37]   Imprint Cytologic Features in Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusion in an Adult A Case Report [J].
Yamaguchi, Tadanori ;
Kuroda, Naoto ;
Imamura, Yoshiaki ;
Hes, Ondrej ;
Kawada, Takako ;
Nakayama, Keizou .
ACTA CYTOLOGICA, 2009, 53 (06) :693-697
[38]   Nephron-sparing surgery in the treatment of pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions [J].
Liu, Chao ;
Zhang, Weiping ;
Song, Hongcheng .
JOURNAL OF PEDIATRIC SURGERY, 2017, 52 (09) :1492-1495
[39]   A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab [J].
Tomioka, Masayuki ;
Nakane, Keita ;
Ozawa, Kaori ;
Iinuma, Koji ;
Suzui, Natsuko ;
Miyazaki, Tatsuhiko ;
Koie, Takuya .
CANCER REPORTS, 2021, 4 (04)
[40]   Estradiol increases risk of topoisomerase IIβ-mediated DNA strand breaks to initiate Xp11.2 translocation renal cell carcinoma [J].
Shi, Qiancheng ;
Liu, Ning ;
Yang, Lei ;
Chen, Yi ;
Lu, Yanwen ;
Guo, Hongqian ;
Han, Xiaodong ;
Li, Dongmei ;
Gan, Weidong .
CELL COMMUNICATION AND SIGNALING, 2021, 19 (01)
12345